pharmaphorum February 20, 2020
A new report lays out the ways digital transformation could reverse the trend of declining ROI in pharma R&D.
R&D costs are skyrocketing. In 2010 the mean cost of bringing a new asset to market was $1.1 billion; in 2018 it was $2.1 billion, with clinical trials making up an increasingly large share of this cost. Meanwhile, the mean projected return on new R&D investments fell to 1.9% from 10.1% in 2010, according to an ongoing analysis by Deloitte.
Tom O’Leary, chief information officer at ICON, says there are a number of factors behind this decline in return on investment (ROI).
“Costs are continuing to increase as more capabilities become available,” he says. “Therapies have become more targeted, and gone...
Today's Sponsors
Today's Sponsor